ZEISS Professional Education

Michael Boland, MD, PhD, Danica J. Marrelli, OD, FAAO, Diplomate, Glaucoma Section, AAO, Diplomate ABO, Shalini Sood-Mendiratta, MD

Join Michael V. Boland, MD, PhD, Danica J. Marrelli, OD, FAAO, Dipl. Glaucoma Section AAO, Dipl. ABO and Shalini Sood, MD as they discuss collaborative care in glaucoma.

Yasha Modi, MD MHS, Carolyn Majcher, OD, FAAO, FORS, Eric Schneider, MD, Michael Boland, MD, PhD, Danica J. Marrelli, OD, FAAO, Diplomate, Glaucoma Section, AAO, Diplomate ABO, Shalini Sood-Mendiratta, MD

Join Yasha S. Modi, MD, MHS, Carolyn E. Majcher, OD, FAAO, Eric W. Schneider, MD, Michael V. Boland, MD, PhD, Danica J. Marrelli, OD, FAAO, Dipl. Glaucoma Section AAO, Dipl. ABO and Shalini Sood, MD as they have a discussion about advanced diagnostics at the 2025 Ophthalmic Medical Education Summit.

Yasha Modi, MD MHS, Carolyn Majcher, OD, FAAO, FORS, Jessica Steen, OD, FAAO, Dipl. ABO

Timely intervention in retinal pathology management is key to preserving patients’ retinas and vision and requires early identification of biomarker changes. As Jessica Steen, OD, FAAO, Dipl. ABO, Carolyn Majcher, OD, FAAO, FORS, and Yasha Modi, MD, MHS, demonstrate, new technologies, such as ocular coherence tomography angiography (OCT-A), offer new insights into the varied ways in which retinal changes can present—including those obscured within the blind spots of other imaging modalities.

Michael Chaglasian, OD, FAAO, Sarah Gleason, OD, FAAO, Dipl. ABO, Wesdon McCann, OD

Michael Chaglasian, OD, FAAO, Sarah Gleason, OD, FAAO, Dipl. ABO, and Wesdon McCann, OD, share some case studies which highlight the varied ways that they have used new and traditional structural biomarkers to diagnose and manage glaucoma in their patients.

Wesdon McCann, OD

Join Wesdon McCann, OD as he discusses glaucoma management.